Asensus Surgical, Inc.
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company’s products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina. As of August 22, 2024, Asensus Surgical, Inc. operates as a subsidiary of KARL STORZ Endoscopy-America, Inc.
Market Cap
$94.9M
Volume
2.0M
Cash and Equivalents
$7.8M
EBITDA
-$67.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$3.0M
Profit Margin
30.45%
52 Week High
$0.40
52 Week Low
$0.17
Dividend
N/A
Price / Book Value
-8.37
Price / Earnings
-1.10
Price / Tangible Book Value
-7.69
Enterprise Value
$92.3M
Enterprise Value / EBITDA
-1.41
Operating Income
-$71.2M
Return on Equity
334.02%
Return on Assets
-76.18
Cash and Short Term Investments
$7.8M
Debt
$5.1M
Equity
-$11.3M
Revenue
$9.8M
Unlevered FCF
-$1.7M
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium